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Abstract 38 
Background 39 
Screening young sexually active adults for genital Chlamydia trachomatis is promoted, but 40 
its population effectiveness is debated. The Australian Chlamydia Control Effectiveness Pilot 41 
(ACCEPt) investigated the effects of opportunistic chlamydia testing in primary care on 42 
chlamydia prevalence, pelvic inflammatory disease (PID) and epididymitis in the population. 43 
Our hypothesis was that if chlamydia testing rates increased sufficiently, the prevalence of 44 
chlamydia in the population would decrease. 45 
 46 
Methods 47 
We conducted a cluster randomised controlled trial. Clusters were rural towns with a 48 
minimum of 500 women and men aged 16-29 years resident and no more than six primary 49 
care clinics. We randomly allocated each cluster using a computer-generated-minimisation 50 
algorithm to receive a clinic-based chlamydia testing intervention or continue usual care. 51 
Clinic staff were aware of the allocation, and posters and information cards in the waiting 52 
room informed patients that the clinic was in a trial of chlamydia testing but did not specify 53 
whether the clinic was intervention or control.  The intervention included computerised 54 
reminders, an education package, payments for chlamydia testing and feedback on testing 55 
rates. The primary outcome was chlamydia prevalence, estimated before randomisation and 56 
at trial end in patients aged 16-29 years attending clinics. Secondary outcomes included 57 
chlamydia testing and the incidence of PID (diagnosed in clinics and hospitals) and 58 
epididymitis (in clinics). Analyses were intention to treat. (Australian Clinical Trial Register 59 
ACTRN12610000297022). 60 
 61 
Findings 62 
Between July 2010 and December 2012, we randomly assigned 26 clusters (63 clinics) to 63 
receive a chlamydia testing intervention and 26 clusters (67 clinics) to continue with usual 64 
care. Overall, 93,828 16 to 29 year olds attended intervention and 86,527 attended control 65 
clinics over a mean of 3·1 years. We collected data for the final outcome measurements 66 
between July 2014 and December 2015. The estimated chlamydia prevalence in 67 
intervention clusters decreased from 5·0% (92/1833) to 3·4% (76/2237, difference −1·6%; 68 
95%CI −2·9 to −0·3), and in control, from 4·6% (88/1925) to 3·4% (589/1716, difference 69 
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−1·1%; 95%CI –2·7 to 0·5). The odds ratio for the difference between intervention and 70 
control clusters was 0·9 (95%CI 0·5 to 1·5). No adverse events were reported by clinics, clinic 71 
staff or patients. 72 
 73 
Interpretation 74 
The ACCEPt results, in conjunction with evidence about the feasibility of sustained uptake of 75 
opportunistic testing in primary care, indicate that sizeable reductions in chlamydia 76 
prevalence or chlamydia-associated complications might not be achievable. 77 
 78 
Funding 79 
Commonwealth Department of Health, National Health and Medical Research Council, 80 
Victorian Department of Health and NSW Ministry of Health.  81 
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Research in context 82 
Evidence before this study 83 
A systematic review of chlamydia screening interventions identified six RCTs published up to 84 
the 14th February 2016, four of which investigated the effect on the incidence of PID of a 85 
single offer of a chlamydia screening test and two which investigated the effect of multiple 86 
rounds of chlamydia screening on chlamydia prevalence. In a meta-analysis, the incidence of 87 
PID was lower in intervention than control groups (risk ratio, RR 0·68; 95%CI 0·49 to 0·94; 88 
I2=8%). However, methodological limitations of the trials could have resulted in an over-89 
estimation of the protective effects of a single chlamydia screening test. A cluster-RCT in 90 
women and men in the general population in the Netherlands found no change in chlamydia 91 
positivity among those tested after three rounds of screening (RR 0·96, 95% CI 0·84 to 1·09). 92 
However, screening uptake was low, with only 16% screened in the first round, falling to 93 
10% in the third round. A cluster RCT of a multifaceted intervention that included syndromic 94 
management for sexually transmitted infections (STIs) among young adults in the 95 
community and STI screening in female sex workers in Peru found no difference in 96 
chlamydia prevalence after four years among young adults but in secondary analyses, found 97 
a reduction among female sex workers (adjusted RR 0·72; 95% CI 0·54 to 0·98). None of the 98 
trials investigated the impact of multiple rounds of testing on both chlamydia prevalence 99 
and the incidence of PID. We searched PubMed from January 1 2016 to February 28 2018 100 
with the terms “chlamydia” and (“randomised controlled trial” or “randomised clinical trial” 101 
or “trial” or “randomly”) and restricted the search to clinical trials in English only. No further 102 
completed trials were identified.  103 
 104 
Added value of this study 105 
The Australian Chlamydia Control Effectiveness Pilot (ACCEPt) is, to our knowledge, the first 106 
RCT to investigate the impact of repeated rounds of testing on the multiple biological 107 
outcomes of chlamydia prevalence, PID and epididymitis. It was a pragmatic trial that 108 
reflected the situation that would occur if an opportunistic chlamydia screening programme 109 
was rolled out. Our chlamydia testing intervention was successfully implemented in 63 110 
clinics, reaching over 90,000 men and women aged 16 to 29 years and increasing absolute 111 
testing rates by 11.9% (from 8.2% to 20.1%), double that achieved in the only other trial of 112 
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multiple rounds of testing in a high-income country. While it did not have a measurable 113 
effect on estimated prevalence of chlamydia in the population, the incidence of PID 114 
requiring hospitalisation decreased by 13·7 per 10,000 (95%CI: −26·9 to −0·5). However, 115 
there was no change in the incidence of PID or epididymitis diagnosed in the clinic.  116 
 117 
Implications of all the available evidence 118 
In high-income countries, the ACCEPt trial results, in conjunction with evidence about the 119 
feasibility of sustained uptake of opportunistic testing in primary care clinics and evidence 120 
from previous trials, indicate that sizeable reductions in chlamydia prevalence or chlamydia-121 
associated complications might not be achievable. 122 
 123 
 124 
  125 
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Introduction 126 
Screening among young sexually active adults is widely promoted to control transmission of 127 
Chlamydia trachomatis,1-3 which causes chlamydia, the most commonly diagnosed bacterial 128 
sexually transmitted infection (STI) in high income countries.1,3,4 Chlamydia is usually 129 
asymptomatic and common in young sexually active women and men, with an estimated 130 
population-based prevalence of 3·1% among women and 2·3% among men aged 16 to 24 131 
years in the UK5 and 4.7% among women aged 14 to 24 years in the USA.6 Screening for 132 
asymptomatic infection aims to prevent pelvic inflammatory disease (PID), which can cause 133 
tubal factor infertility and ectopic pregnancy. Treatment of a sufficiently large number of 134 
infections should limit transmission and reduce prevalence.   135 
 136 
The effectiveness and cost-effectiveness of chlamydia screening interventions are 137 
debated.7,8 In randomised controlled trials (RCTs), a single round of screening and treatment 138 
reduced the incidence of PID, although the effect might have been overestimated.7 Multiple 139 
rounds of screening did not reduce population chlamydia prevalence in young adults, but 140 
screening coverage in one trial was very low.9 Given the uncertainty about the effects of 141 
multiple rounds of screening on both PID and on chlamydia prevalence, additional evidence 142 
is needed. The objective of the Australian Chlamydia Control Effectiveness Pilot (ACCEPt) 143 
was to investigate the effect of opportunistic testing in primary care clinics on C trachomatis 144 
prevalence, PID and epididymitis in the population. Our hypothesis was that if chlamydia 145 
testing rates increased sufficiently, the population-based prevalence of chlamydia would 146 
decrease. 147 
 148 
Methods 149 
The trial protocol trial can be found at http://www.thelancet.com/protocol-reviews/12PRT-150 
9010.10 We report the trial according to the CONSORT extension for cluster RCTs.  151 
 152 
Study design  153 
ACCEPt was a pragmatic cluster RCT targeting sexually active women and men aged 16 to 29 154 
years for annual chlamydia testing at primary care clinics in the Australian states of New 155 
South Wales, Victoria, South Australia and Queensland. Rural towns were chosen as clusters 156 
because they are geographically separated to minimise contamination and all clinics in a 157 
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town could be enrolled. About 25% of Australia’s population lives in rural areas. Primary 158 
care clinics included general practices and Aboriginal medical services. General practitioners 159 
(GPs) in Australia provide most primary care, including over 80% of testing for STIs. Most 160 
general practices in Australia are businesses with varying numbers of GPs, nurses and 161 
support staff. About 5% of towns in ACCEPt had an Aboriginal medical service. We enrolled 162 
clinics between July 2010 and December 2012 for baseline measurements, and collected 163 
final outcome data between July 2014 and December 2015. 164 
 165 
The Royal Australian College of General Practitioners (RACGP) National Research and 166 
Evaluation Ethics Committee and the Aboriginal Medical Research Council approved the 167 
trial. The trial is registered with the Australian Clinical Trial Register 168 
(http://www.anzctr.org.au), number ACTRN12610000297022.  169 
 170 
Clusters, primary care clinics, GPs and patients 171 
Clusters were rural towns, defined by postcode boundaries (remoteness area 2-5 in the 172 
Australian Statistical Geography Standard), with a minimum of 500 men and women aged 173 
16 to 29 years old at the 2006 census and no more than six clinics. Towns were ineligible if 174 
their primary economic activity was mining, military or tourism.  175 
 176 
Within each cluster we invited all primary care clinics. If a clinic refused to participate, the 177 
cluster was ineligible. GPs gave written consent to implement the intervention or control at 178 
the clinic level and to provide access to their consultation and chlamydia testing data. New 179 
clinics in each cluster and new GPs during the trial were recruited. 180 
 181 
Men and women attending clinics for any consultation during the intervention period were 182 
eligible for one chlamydia test per year, regardless of symptoms or contact history, if they 183 
were aged 16 to 29 years and had ever had vaginal or anal intercourse. We collected de-184 
identified data about consultations from electronic patient records. 185 
 186 
Randomisation and masking 187 
A statistician, located at a site away from the clusters, generated the randomisation 188 
sequence using a computer-generated minimisation algorithm. The algorithm aimed to 189 
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achieve balance for three pre-specified variables: i) estimated chlamydia prevalence (<3% 190 
vs. ≥3%, based on an earlier study);11 ii) chlamydia testing rate (<6% vs. ≥6% based on data 191 
from rural primary care clinics in 2008);12 and iii) number of 16 to 29 year olds in the town 192 
(<2000 vs. ≥2000, the 75th percentile of population size in eligible postcodes). The 193 
statistician ran the randomisation algorithm after the baseline estimation of chlamydia 194 
prevalence in each cluster and informed research staff of the allocation who in turn notified 195 
clinics. GPs and clinic staff were aware of the allocation. Posters and information cards in 196 
waiting rooms informed patients that the clinic was taking part in a trial of chlamydia testing 197 
but did not specify whether the clinic was in the intervention or control. Pathology 198 
laboratories conducting the testing were not informed of the allocation.   199 
 200 
Procedures 201 
We developed a multifaceted intervention package to encourage staff to offer annual 202 
chlamydia testing to all eligible patients, based on evidence from systematic reviews and 203 
considerations of long-term feasibility in Australian primary care.13 Guided by normalisation 204 
process theory, the research team worked with each clinic to tailor the intervention to the 205 
clinic and embed it into routine practice.14 The intervention package (see protocol) 206 
included:10 an education package for GPs and nurses about strategies for offering testing for 207 
chlamydia, management of infection and partner notification; clinical criteria for PID and 208 
epididymitis diagnosis; payments for GPs (AUD$5, $7 or $8 per test where <20%, 20-40% or 209 
>40% of eligible patients were tested, respectively); payments for nurses (AUD$10 for each 210 
test); quarterly written feedback to GPs on their testing rates discussed in a face-to-face 211 
meeting between a research staff member and GPs; a computer alert prompting testing 212 
with eligible patients; support to develop a reminder system to recall patients after 12 213 
months if chlamydia negative or after three months if treated for chlamydia; and partner 214 
notification information and resources, including access to www.letthemknow.org.au.  215 
 216 
Research staff instructed control clinics to test for and manage chlamydia according to their 217 
usual practice. GPs received a minimal education package with clinical criteria for PID and 218 
epididymitis diagnosis to minimise measurement bias for these conditions, but they did not 219 
receive any other elements of the intervention package. 220 
 221 
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In both intervention and control clinics, we instructed staff to test for chlamydia using 222 
patient-collected urine specimens or vaginal swabs. Diagnosis was based on nucleic acid 223 
amplification tests (NAAT) conducted by the clinic’s usual pathology provider. Clinics were 224 
instructed to treat and manage chlamydia according to Australian guidelines,15 with a single 225 
one gram dose of azithromycin, and to initiate partner notification. 226 
 227 
Trial outcomes 228 
The primary outcome was chlamydia prevalence in the population served by the clinics in 229 
each cluster. We assumed that the proportion of positive chlamydia tests among people 230 
attending the clinic would provide an estimate of the population prevalence. We used the 231 
same method to estimate the prevalence of C trachomatis before randomisation (survey 1) 232 
and at the end of the intervention period (survey 2). See Yeung et al. for further detail on 233 
prevalence survey methods,16 but in brief, a member of the research team invited 234 
consecutive patients in the clinic waiting room to participate, assessed eligibility, and 235 
obtained written consent. People attending clinics for a consultation were eligible if they 236 
were aged 16 to 29 years and had ever had vaginal or anal intercourse. The research 237 
member was based at each clinic for up to six weeks to enrol the target number of 238 
participants. Researchers recorded non-participants’ age and gender. Participants provided 239 
a self-collected specimen for testing.  240 
 241 
Outcome definitions are described in the protocol.10 The primary outcome, C trachomatis 242 
prevalence, was estimated as the proportion of women and men aged 16 to 29 years in the 243 
surveys with a positive chlamydia test result. Secondary outcomes were measured at the 244 
cluster level: incidence of PID in clinics or hospitals or epididymitis in clinics, yearly 245 
chlamydia test uptake, chlamydia positivity among those tested, chlamydia re-testing 10-15 246 
months after a negative test or re-testing six weeks to six months after a positive test, and 247 
repeat chlamydia diagnosis. We installed data extraction software (GRHANITETM 248 
www.grhanite.com) on computers, which extracted anonymised patient information from 249 
12 months before recruitment until trial end.   250 
 251 
We collected PID data from two sources: participating clinics and hospitals. These data could 252 
not be combined because they were measured in different ways. At clinics, we measured 253 
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the incidence proportion (cumulative incidence) of PID diagnosed among women aged 16 to 254 
33 years over the intervention period. The denominator was the number of female patients 255 
aged 16 to 33 years with at least one consultation during the intervention period. Given the 256 
uncertainty about when PID occurs following chlamydia infection,17 the upper age limit 257 
allowed for infection among women aged 26 to 29 years at start of the trial, who might have 258 
developed PID during the intervention period. GPs were advised to use the United States 259 
Centers for Disease Control and Prevention clinical criteria to diagnose PID.18 In hospitals, 260 
we used ICD10 codes to measure the incidence proportion of PID among women living in 261 
each cluster,19 obtained from each State health department, based on primary diagnoses of 262 
PID. The age range for the numerator and denominator for hospitalisation data was 15 to 34 263 
years because these data were only available aggregated in 5-year age groups. 264 
 265 
We measured the incidence proportion of epididymitis among men aged 16 to 29 years 266 
attending clinics during the intervention. The denominator was the number of male patients 267 
aged 16 to 29 years with at least one consultation at the clinic during the intervention 268 
period. The upper age limit was 29 years because epididymitis is usually an acute condition 269 
associated with a current chlamydia infection.20 The diagnosis of epididymitis was based on 270 
signs and symptoms as defined in Australian guidelines.15  271 
 272 
Definitions of all other secondary outcomes are listed in the protocol.10 273 
 274 
Statistical analysis 275 
We based the sample size on an assumption of an absolute difference of 2% in estimated 276 
chlamydia prevalence at the end of the trial (4% in control and 2% intervention clusters).11,21 277 
We needed 52 clusters with an average of 80 women and men aged 16 to 29 years tested 278 
for chlamydia per cluster to detect a difference of this size with 80% power and 5% 279 
significance, based on an intra-class correlation coefficient (ICC) of 0·009.11 The number of 280 
patients enrolled at each clinic was proportional to the number of 16 to 29 year olds in the 281 
clinic database. This sample size allowed us to estimate chlamydia prevalence with precision 282 
of ±0.5%. 283 
 284 
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We analysed trial results according to intention to treat. We used generalised linear models 285 
that accounted for clustering using the generalised estimating equation approach, with 286 
robust standard errors. We fitted an unadjusted model as the initial analysis for each 287 
outcome. For the primary outcome, estimated chlamydia prevalence, we also fitted a 288 
multivariable model to control for imbalances in cluster-level baseline covariates 289 
(socioeconomic status) and potential individual level confounding factors such as gender, 290 
age group, number of sex partners in the last 12 months, condom use last encounter, clinic 291 
attendance for a sexual health reason and antibiotic use in the last three months. For 292 
secondary outcomes, the multivariable models included gender, age group, and 293 
socioeconomic status of the area served by the clinic.  294 
 295 
We calculated the absolute difference in chlamydia prevalence between survey 1 and survey 296 
2 with 95% confidence intervals (CI) for intervention and control clusters using the binomial 297 
error distribution with the identity link function. We calculated the absolute difference for 298 
the prevalence treatment effect, PID, and epididymitis using the identity link function. The 299 
relative difference between intervention and control clusters was estimated as an odds ratio 300 
(OR, prevalence, testing, retesting, repeat infection) using the binomial error distribution 301 
with the logit link function or risk ratio (PID, epididymitis) using the Poisson error 302 
distribution with the log link function, with 95% CI and p‐values from the corresponding 303 
hypothesis tests. Statistical significance was taken as a two-sided p‐value less than 0.05, 304 
with no adjustment for multiple comparisons. Specific models for each secondary outcome 305 
are described in the protocol.10 306 
 307 
We pre-specified exploratory analyses of the effect of the intervention in different 308 
subgroups for the primary outcome (gender, age group, estimated baseline chlamydia 309 
prevalence and baseline testing rate) and secondary outcomes (gender and age group). We 310 
used tests for interaction to examine evidence for heterogeneity of effects between 311 
intervention allocation and each subgroup. In addition, we conducted a pre-specified 312 
secondary analysis of the primary outcome to explore the effect of adherence to the 313 
intervention by excluding intervention clinics that had testing rates below the 25% 314 
percentile in the final year (10.7%) and control clinics that had testing rates above this 315 
cutpoint.   316 
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 317 
We used SAS Version 9.1 for most analyses. We used STATA/SE Version 14.2 to analyse PID 318 
hospitalisation data and R Version 3.3.1 to obtain the intra-cluster-correlation coefficient.   319 
 320 
Deviations from the protocol 321 
There were no deviations in trial implementation. Our statistical analysis plan did not 322 
explicitly state the reporting of absolute differences but these are included as good 323 
reporting practice.   324 
 325 
Role of the funding source 326 
Australian Government Department of Health, National Health and Medical Research 327 
Council, Victorian Department of Health and New South Wales Ministry of Health funded 328 
ACCEPt. The RACGP and Australian Primary Care Nurse Association provided additional in-329 
kind support. The funding bodies had no role in study design, data collection, data analysis, 330 
data interpretation or writing of this paper. The corresponding author had access to all data 331 
and responsibility for the decision to submit for publication. 332 
 333 
Results  334 
We enrolled 130 clinics in 54 postcode areas and 87% of clinics approached agreed to 335 
participate. We merged four neighbouring towns into two clusters because of close 336 
proximity (<40 kms) and randomised 52 clusters to intervention or control (Figure 1). The 337 
mean distance by road between an intervention and a control cluster was 830 kms (SD 513; 338 
range 40 to 2136 km). The intervention period in each cluster ranged from 2·5 to 4·2 years 339 
with a mean of 3·1 years (SD 0·3). Three clinics in different control clusters (2·3%) withdrew 340 
from the trial. 341 
 342 
Baseline characteristics of clusters and GPs in intervention and control clusters were 343 
comparable (Table 1). The response rates and characteristics of participants in surveys 1 and 344 
2 were comparable between intervention and control and between the two surveys. Given 345 
the comparability at cluster, clinic and individual level, we report results from the 346 
unadjusted models. Findings from the adjusted models are shown in the tables. 347 
 348 
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We enrolled 3,758 patients into survey 1 and 3,953 into survey 2. In each survey, women 349 
were more likely to participate: survey 1, 72·5% women vs 65·7% of men; survey 2, 72·4% of 350 
women vs 63·7% of men. The median ages of those who refused and those who participated 351 
was 23 years in both surveys. The intra-class correlation for chlamydia prevalence was 0·004 352 
(SE 0·002) for survey 1 and 0.001 (SE 0·002) for survey 2.  353 
 354 
Between surveys 1 and 2, the estimated chlamydia prevalence in intervention clusters 355 
decreased from 5·0% (92/1833) to 3·4% (76/2237) (difference −1·6%, 95% CI −2·9% to 356 
−0·3%) and, in control, from 4·6% (88/1925) to 3·4% (59/1716) (difference −1·1% 95% CI 357 
−2·7% to 0·5%) (Table 2, Figure S1). The absolute difference in treatment effect between 358 
intervention and control was estimated as –0·5 (95% CI −2·6 to 1·5; relative difference OR 359 
0·9; 95%CI 0·5 to 1·5). In subgroup analyses, there was no evidence of differences in the 360 
treatment effect between the intervention and control when stratified by gender, age, 361 
Aboriginal status, baseline chlamydia prevalence or baseline chlamydia testing rate 362 
(Supplementary Table S2). In a secondary analysis of adherence to the intervention, we 363 
estimated an OR of 0·7 (95% CI 0·3 to 1·6) for the relative difference in the treatment effect 364 
between intervention and control (Supplementary Table S3).   365 
 366 
For PID diagnosed in clinics, the incidence estimates in intervention and control clusters 367 
were similar, difference 5·5 per 10,000 (95% CI −13·4 to 24·3) (Table 2, Figure S2). For PID 368 
diagnosed in hospitals, the incidence was lower in intervention (24·2 per 10,000 over 3 369 
years follow-up) than control clusters (37·9 per 10,000 over 3 years follow-up; difference 370 
−13·7 per 10,000, 95% CI −26·9 to −0·5).  For epididymitis diagnosed in clinics, the incidence 371 
was similar in intervention and control clusters (difference −1·6 per 10,000, 95% CI −12·4 to 372 
9·1) (Table 2, Figure S2).   373 
 374 
Among 93,828 patients aged 16 to 29 years who attended intervention clinics at least once 375 
during the trial, 22,769 had at least one chlamydia test (67·8% had one, 20·7% had two and 376 
11·5% had three or more tests). Among 86,527 patients attending control clinics, 14,774 had 377 
at least one chlamydia test (70·7% had one, 19·6% had two and 9·7% had three or more 378 
tests). The proportion of patients tested increased each year: in intervention clusters from 379 
8·2% (95% CI 7·0 to 9.4) to 20·1% (95% CI 18·4 to 21·8; difference 11·9%, 95%CI 10·3 to 13·4) 380 
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and in control from 8·2% (95% CI 7·2 to 9·2) to 12·9% (95% CI 11·2 to 14·5; difference 4·6%; 381 
95% CI 3·3 to 6·0). The increase was greater in intervention than control clusters (OR 1·7, 382 
95% CI 1·4 to 2·1, in the final year) (Figure 2A, Supplementary Table S1). Chlamydia testing 383 
uptake increased in both sexes and across age groups (Figure 2B, 2C and Supplementary 384 
Table S4). Chlamydia positivity decreased in both intervention and control clusters and, in 385 
the final year, was lower in intervention clusters (6·8%, 95% CI 5·6 to 8·0) than control 386 
(8·8%, 95% CI 7·7 to 9·9; OR 0·8; 95%CI 0·6 to 1·0) (Supplementary Table S1). Chlamydia 387 
positivity was higher in men than women at all time points and highest among 16 to 19 year 388 
olds (Supplementary Table S5). 389 
 390 
The proportion of patients who had a repeat test within 10 to 15 months of a negative 391 
chlamydia test result was higher in intervention than control clusters throughout the 392 
intervention period (Supplementary Table S1). The highest proportion was 10·4% (95% CI 393 
8·7 to 12·1) after year one in intervention clusters and declined to below 4·0% in both 394 
groups by the final year. Among patients with a positive chlamydia test, the proportion with 395 
a repeat test within six weeks to six months was higher in intervention than control 396 
throughout the intervention period (Supplementary Table S1). The odds of a repeat positive 397 
chlamydia test after retesting was similar in intervention and control clusters during the 398 
intervention period (Supplementary Table S1).  399 
 400 
No adverse events were reported by clinics, clinic staff or patients 401 
 402 
Discussion 403 
We implemented a pragmatic multifaceted chlamydia testing intervention in 63 primary 404 
care clinics, reaching over 90,000 men and women aged 16 to 29 years, with an absolute 405 
increase in testing of 11·9% (to 20.1%) over a mean of 3·1 years follow-up. The estimated 406 
prevalence of chlamydia declined in both intervention (absolute difference −1·6%) and 407 
control clusters (absolute difference −1·1%). The incidence of PID-related hospitalisations 408 
was 40% lower (absolute difference −13·7 per 10,000) in intervention than control clusters, 409 
but the incidence of PID and epididymitis diagnosed in clinics were similar.  410 
 411 
Page 15 of 37 
 
ACCEPt has several strengths. First, it is the only RCT to have evaluated the effects of several 412 
rounds of opportunistic chlamydia screening on multiple outcomes of chlamydia prevalence, 413 
PID and epididymitis. Second, ACCEPt shows the value of randomisation. In a before-and-414 
after design, without a control arm, the reduction in estimated chlamydia prevalence would 415 
have been assumed to have resulted from increased testing. Third, the pragmatic 416 
implementation and evaluation reflect the situation that would occur if a chlamydia 417 
screening programme was rolled out, with the addition of theory-based implementation 418 
into routine practice.14 Fourth, cluster randomisation meant that all clinics in a town were 419 
offered the same intervention package. Measurement of an infectious disease outcome at 420 
the cluster level also captured the effects on transmission within social and sexual networks. 421 
To our knowledge, this trial provides the least biased estimate to date of the effectiveness 422 
of an intervention to increase opportunistic chlamydia testing. Measures to minimise bias 423 
included enrolment of all clinics in a cluster to reduce contamination, allocation 424 
concealment, use of routine data to minimise measurement bias and blinding of the 425 
statistician in the analysis.  426 
 427 
The trial also had limitations. First, we estimated chlamydia prevalence in the population by 428 
conducting a survey in attenders at clinics, and only about 30% of those who took part were 429 
men, reflecting clinic attendance patterns. To increase external validity, we enrolled 430 
consecutive patients, irrespective of the reason for consultation; response rates were high, 431 
about 70% in each survey and measured characteristics of participants in both surveys were 432 
similar. Second, our sample size assumed an absolute reduction in estimated chlamydia 433 
prevalence of 2% in the intervention and no change in the control. We did not anticipate a 434 
decrease in both groups. Nevertheless, we can rule out baseline differences as a source of 435 
uncertainty because we estimated chlamydia prevalence at the start and end of the trial and 436 
there were no important baseline imbalances between groups. Third, the trial was 437 
conducted in rural towns so the results might not be generalisable to more ethnically and 438 
socio-economically diverse urban areas. However, we accounted for area level socio-439 
economic factors in our analysis. Fourth, we could not eliminate ascertainment bias from 440 
the diagnosis of PID within clinics because clinical judgment can be influenced by knowledge 441 
of a woman’s chlamydia test status. Fifth, we were unable to collect data on partner 442 
notification nor confirm treatment of all diagnosed cases, but, data from primary care in 443 
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Australia suggest nearly all cases are treated.22 Finally, as our intervention was pragmatic 444 
and modified as clinics’ needs changed, we could not determine which intervention 445 
components were the most effective at increasing test uptake. 446 
 447 
ACCEPt is one of the few controlled trials to have evaluated the effects of chlamydia testing 448 
on prevalence. The Dutch Chlamydia Screening Implementation (CSI) trial evaluated yearly 449 
register-based invitations to 16 to 29 year old women and men using self-collected 450 
specimens.9 Uptake was too low to estimate chlamydia prevalence in the population, so the 451 
investigators reported the proportion of chlamydia tests with a positive result (chlamydia 452 
positivity) and found no difference between intervention and control areas, with poor 453 
uptake as a possible explanation. Baseline chlamydia positivity in ACCEPt (4·8%, 180/3758) 454 
and the first CSI screening round (4·3%, 1851/43358) were similar. Unlike CSI, chlamydia 455 
positivity in ACCEPt declined over time. This was not unexpected because, as testing rates 456 
increase, the inclusion of lower risk individuals will decrease chlamydia positivity. The 457 
reduction in the incidence of PID hospitalisation (RR 0·6, 95% CI 0·4 to 1·0) in ACCEPt was 458 
compatible with the relative risk in a meta-analysis of previous trials.7 However, the 459 
incidence of PID was low and the absolute difference was small (13·7 per 10,000 after a 460 
mean of 3.1 years). One trial in Denmark that used routine data to estimate PID incidence 461 
from hospital and community records, found comparably low rates of PID (around 50 per 462 
10,000 women) but no difference between control and intervention (hazard ratio 1·12, 95% 463 
CI 0·7 to 1·8).23 Neither ACCEPt nor the Danish trial found an effect of chlamydia testing on 464 
epididymitis in men.  465 
 466 
The ACCEPt intervention did not result in a clinically relevant difference in estimated 467 
chlamydia prevalence between intervention and control clusters after three years. An 468 
important reason might be that testing uptake needed to be sustained at higher levels for 469 
longer, with higher levels of repeat testing. Our mathematical modelling suggested that 470 
uptake of 20% by women and men under 30 years could reduce population prevalence by 471 
65% in 10 years.21 Our intervention increased uptake to an average of 20%, which may have 472 
increased further over time. Larger financial incentives might have increased testing rates 473 
more, but at the time of the trial, our incentive payments were based on what was offered 474 
for immunisation and other similar preventive activities in general practice. A one-year pilot 475 
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for the National Chlamydia Screening Programme in England achieved uptake of 45% with 476 
GP incentives of up to £25 per test.24 These payments were not sustained during the roll-out 477 
with testing rates in general practice falling to below 10%.25 The effects of higher levels of 478 
test uptake on population prevalence of chlamydia remain unclear. In Great Britain, 479 
population chlamydia prevalence in women aged 18 to 24 years was 3·1% in 1999 to 2000 480 
and 3·2% in 2010 to 2011,5 during which testing coverage increased from 8% in 2008 to 481 
about 30% in 2011.25 In the United States of America, population chlamydia prevalence 482 
among women aged 15 to 24 years was 4·1% (95% CI 2·4 to 6·8) in 1999 to 2000 and 3·8% 483 
(95% CI 2·4 to 6.0) in 2007 to 2008,26 when testing coverage among women aged 15 to 24 484 
years was reported to be more than 35% per year.27   485 
 486 
Reasons for the reduction in estimated chlamydia prevalence in both intervention and 487 
control clusters, despite marked differences in test uptake, are unclear. We do not think 488 
that awareness about the intervention or information given to control clusters contributed 489 
to the reduction in prevalence for two reasons. First, only GPs in intervention clusters 490 
received education about chlamydia testing and management and the PID and epididymitis 491 
package included only information about criteria for diagnosis. Second, testing uptake did 492 
not increase after survey 1. It is possible that treatment of chlamydia detected during the 493 
first survey removed prevalent infections from the population, with insufficient time 494 
between the surveys for rebound. The geographical separation of rural towns in Australia 495 
might have reduced the opportunity for new infections to be introduced and, in survey 2, 496 
78% of participants reported that their most recent sexual partner came from within the 497 
same postcode. However, the surveys only included about 10% of all patients registered at 498 
the clinics, so a marked reduction in C trachomatis transmission at the population level is 499 
unlikely. Background antibiotic use may have affected both intervention and control, 500 
particularly as the second survey took place during a severe influenza season.28 We think 501 
that antibiotic use is an unlikely explanation because prescribing increased by only 5·6% 502 
across Australia between surveys,29 chlamydia notifications in the population as a whole did 503 
not decline,4 and statistical adjustment for reported antibiotic use in both surveys did not 504 
affect our results. Regression to the mean, affecting both intervention and control, is the 505 
most likely explanation. It is also possible that participants in survey 1 were at higher risk of 506 
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chlamydia than those in survey 2, even though participation rates and measured 507 
characteristics were similar. 508 
 509 
The ACCEPt intervention was an intensive but highly pragmatic package that can be adapted 510 
to different primary care clinics. Although it increased levels of opportunistic chlamydia 511 
testing, it is likely that substantial investment would be required to increase and maintain 512 
test coverage at higher levels. An ongoing economic evaluation will determine its cost-513 
effectiveness. In high income countries with a low general population chlamydia prevalence, 514 
public health specialists and policy makers should decide on an acceptable level for 515 
chlamydia control and focus on the reduction of social and ethnic inequalities in chlamydia 516 
and its associated complications.30 The ACCEPt results, in conjunction with evidence about 517 
the feasibility of sustained uptake of opportunistic testing in primary care clinics, indicate 518 
that substantial reductions in chlamydia prevalence or chlamydia-associated complications 519 
might not be achievable. 520 
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Figure 1: Flow chart 642 
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A) 644 
 645 
 646 
B) 647 
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 649 
C) 650 
Figure 2: Chlamydia testing per 100 per year by time since randomisation – A) Overall, B) Females, C) 651 
Males. (Time since randomisation refers to time since the start of the intervention period in each cluster and is 652 
defined as:  -1 is defined as the (24-13) months before randomisation; 0 is defined as (12-1) months before 653 
randomisation, prevalence survey 1 was conducted during this time; 1 as (1-12) months after randomisation; 2 654 
as (13-24) months after randomisation; 3 as (25-36) months after randomisation. 655 
  656 
Page 25 of 37 
 
 657 
Supplementary Figure S1: Primary outcome – chlamydia prevalence 658 
 659 
 660 
Supplementary Figure S2: Secondary morbidity outcomes (PID-clinic – incidence of PID diagnosed at 661 
participating clinics; PID-hospitalisation – incidence of PID associated hospitalisations; Epididymitis-clinic – 662 
incidence of epididymitis diagnosed at participating clinics) 663 
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Table 1:  Baseline characteristics of clusters and clinics and characteristics of those participating in each 665 
prevalence survey  666 
Variable Intervention Control Australian 
average§ 
Number of clusters 26 26 - 
Number of clinics at randomisation 63 67 - 
Number of GPs* 305 281 - 
GPs who are female n (%)* 120 (39) 112 (40) 41% 
GP age group (n, %)* 
≤44 yrs. 
45-59 yrs. 
≥60 yrs. 
 
149 (49) 
131 (43) 
25 (8) 
 
145 (52) 
110 (39) 
26 (9) 
 
33% 
45% 
22% 
Socioeconomic status of clusters n (%)† 
Relatively most disadvantaged Q1 
Q2 
Q3 
Q4 
Relatively least disadvantaged Q5 
 
9 (35) 
14 (54) 
 2 (8) 
 1 (4) 
 0 (0) 
 
7 (27)  
14 (54)  
5 (19) 
0 (0)  
0 (0)   
 
 
- 
Remoteness area of clusters n (%)‡ 
Inner Regional 
Outer Regional 
Remote 
 
14 (54) 
11 (42) 
1 (9) 
 
12 (46) 
12 (46) 
2 (8) 
 
- 
Total population 16 to 29 year olds§ 
16-19 yrs n(%) 
20-24 yrs n(%) 
25-29 yrs n(%) 
Females n(%) 
 
10288 (34) 
9912 (32) 
10327 (34) 
14798 (49) 
 
11924 (36) 
10407 (32) 
10480 (32) 
15961 (49) 
 
Chlamydia testing in the 12 months prior to 
recruitment n/N, % (95%CI)|| 
2802/34143  
8·2 (7·0 to 9·4) 
3107/37775 
8·2 (7·2 to 9·2) 
- 
Chlamydia prevalence prior to randomisation 
n/N, % (95%CI) ¶ 
92/1833  
5·0 (3·8 to 6·2) 
88/1925 
4·6 (3·5 to 5·7) 
- 
Prevalence survey 1 
No· of participants in the analysis 1833 1925 - 
Response rate % (95%CI) 68·8 (61·7 to 75·1) 71·8 (66·9 to 76·3)  
Females n (%) 1276 (70) 1394 (72) - 
Age group n (%) 
16-19 yrs. 
20-24 yrs. 
25-29 yrs. 
 
432 (24) 
714 (39) 
687 (37) 
 
521 (27) 
697 (36) 
707 (37) 
 
- 
No· of partners last 12 months n (%) 
Missing 
0/1 
2 
3+ 
 
199 (11) 
1109 (68) 
253 (15) 
272 (17) 
 
166 (9) 
1201 (68) 
267 (15) 
291 (17) 
 
- 
Prevalence survey 2 
No· of participants in the analysis 2237 1716 - 
Response rate % (95%CI) 72 (67·4 to 76·5) 67 (61·0 to 72·0)  
Females n (%) 1616 (72) 1229 (72) - 
Age group n (%) 
16-19 yrs. 
20-24 yrs. 
25-29 yrs. 
 
570 (25) 
834 (37) 
833 (37) 
 
424 (25) 
696 (41) 
596 (35) 
 
- 
No· of partners last 12 months n (%) 
Missing 
0/1 
2 
3+ 
 
182 (8) 
1458 (71) 
255 (12) 
342 (17) 
 
119 (7) 
1104 (69) 
204 (13) 
289 (18) 
 
- 
CI = confidence interval. NB: Not all percentages add up to 100% because of rounding. 667 
* Based on the number of GPs recruited at baseline. General practice is dynamic with GPs departing and/or 668 
joining clinics throughout the trial. Over 1200 GPs were recruited during the trial. † Socioeconomic status based 669 
on quintiles (Q) of each cluster’s index of relative socio-economic disadvantage Australian Bureau of Statistics. 670 
Socio-Economic Indexes for Areas (SEIFA) (2011).  ‡ Remoteness area is based on the Australian Statistical 671 
Geography Standard Remoteness Structure of each cluster. Australian Bureau of Statistics. Australian Statistical 672 
Geography Standard (ASGS): Remoteness Structure, (2011). § Population of 16 to 29 year old men and women 673 
in the cluster. Australian Bureau of Statistics. Population by Age and Sex,  Australian States and Territories. 674 
(2006). It includes people who have never been sexually active. || n= number of patients aged 16 to 29 years 675 
who had at least one chlamydia test in the 12 months prior to the clinic’s recruitment. ¶ Based on prevalence 676 
survey 1 results: n=number of people who test NAAT positive for chlamydia; N=number of people tested. § 677 
Australian National GP Workforce Statistics 2010-2011.  Department of Health. GP Workforce Statistics – 678 
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2001-02 to 2016-17. 2017. 679 
http://health.gov.au/internet/main/publishing.nsf/Content/General+Practice+Statistics-1680 
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Table 2: Primary and morbidity secondary outcomes 
 Intervention Control Unadjusted Adjusted 
Treatment effect Treatment effect 
Primary outcome n/N Prevalence (%) 
(95%CI) 
n/N Prevalence (%) 
(95%CI) 
OR* 
(95% CI) 
P value OR* 
(95% CI) 
P value 
Chlamydia prevalence 
Survey 1 
Survey 2 
Difference: survey 2-survey 1 
 
92/1833 
76/2237 
 
5·0 (3·8 to 6·2) 
3·4 (2·7 to 4·1) 
 –1·6 (–2·9 to –0·3) 
 
88/1925 
59/1716 
 
4·6 (3·5 to 5·7) 
3·4 (2·4 to 4·5) 
–1·1 (–2·7 to 0·5) 
 
 
0·9 (0·5 to 1·5) 
 
 
0·6522 
 
 
0·9 (0·5 to 1·6)† 
 
 
0·6727 
Treatment effect: difference (intervention-control) –0·5 (95%CI: –2·6 to 1·5 p=0·6097)‡  
Secondary outcomes – morbidity n/N Incidence  
(95%CI) 
n/N Incidence  
(95%CI) 
RR|| 
(95% CI) 
P value RR|| 
(95% CI) 
P value 
PID incidence per 10,000 over 3 years- clinic§ 
 
239/65519 44·7 (28·7 to 60·7) 237/60384 39·2 (28·1 to 50·4) 1·1 (0·7 to 1·8) 0·5622 1·2 (0·8 to 1·9)** 0·4553 
Difference (intervention-control) 5·5 per 10,000 (95%CI: –13·4 to 24·3 p=0·5693)§§  
PID incidence per 10,000 over 3 years– hospital¶ 57/23527 24·2 (17·2 to 34·1) 88/23219 37·9 (28·9 to 49·7) 0·6 (0·4 to 1·0) 0·0444 0·6 (0·4 to 1·0)†† 0·0407 
Difference (intervention-control) –13·7 per 10,000 (95%CI: –26·9 to –0·5 p=0·0423)§§  
Epididymitis incidence per 10,000 over 3 years-clinic‡‡ 106/41168 25·7 (17·2 to 34·3) 106/38717 27·4 (20·3 to 34·4) 0·9 (0·6 to 1·4) 0·7676 0·9 (0·6 to 1·4)** 0·6790 
Difference (intervention-control) –1·6 per 10,000 (95%CI:  –12·4 to 9·1 p=0·7660)§§     
OR = Odds Ratio; RR = Risk Ratio; CI = Confidence Interval 
* OR is for the interaction between randomisation group and survey 1 versus 2. † The adjusted model includes gender, age group, number of opposite lifetime partners, 
number of opposite sex partners in the last 12 months, condom use last encounter, sexual health related concerns, any antibiotic use last 3 months, and socioeconomic status 
of clusters. ‡ Unadjusted treatment effect calculated as the difference between survey2 – survey1 for intervention clusters and survey 2 – survey 1 for control clusters.. § 
Based on diagnoses recorded in the medical records software at each clinic. Incidence is a measure of the incidence proportion among women attending the clinic during a 3 
year intervention period. Age group is limited to those aged 16 to 33 years. ¶ Any hospital admission for a primary diagnosis based on the following ICD-10 codes: ICD10 
codes N70.0, N70.1, N70.9, N71.0, N71.1, N71.9, N73.0, N73.1, N73.2, N73.3, N73.4, N73.5, N73.8, N73.9, A56.1, N74.4. Age group is limited to those aged 15 to 34 
years. Incidence is a measure of the incidence proportion among those attending the hospital during a 3 year intervention period. || RR is for intervention versus control. ** 
The adjusted model contains age group and socioeconomic status of cluster.  †† The adjusted model contains age group only.  ‡‡ Based on diagnoses recorded in the medical 
records software at each clinic. Incidence is a measure of the incidence proportion among men attending the clinic during a 3 year intervention period. Age group is limited to 
those aged 16 to 29 years. §§Unadjusted absolute difference between intervention and control incidence. 
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Supplementary Table S1: Secondary outcomes – chlamydia testing, positivity, re-testing and repeat infection 
 Intervention Control Unadjusted Adjusted 
Treatment effect              Treatment effect 
 
 
n/N  
 
Proportion (%) 
(95%CI) 
n/N  
 
Proportion (%) 
(95%CI) 
OR* 
(95% CI) 
P value OR* 
(95% CI) 
P value 
Chlamydia testing by time since randomisation †         
–1 2802/34143   8·2 (7·0 to 9·4) 3107/37775   8·2 (7·2 to 9·2) 1·0 (0·8 to 1·2)  0·9810 1·0 (0·9 to 1·3)¶ 0·6733 
0 5893/42418 13·9 (12·8 to 15·0) 6115/44262 13·8 (12·5 to 15·2) 1·0 (0·9 to 1·2) 0·9277 1·0 (0·9 to 1·2)¶ 0·7109 
1 6264/43968 14·2 (12·6 to 15·9) 5005/44666 11·2 (9·5 to 12·9) 1·3 (1·1 to 1·6) 0·0093 1·4 (1·1 to 1·7)¶ 0·0045 
2 8494/44005 19·3 (16·7 to 21·9) 5090/43438 11·7 (10·1 to 13·3) 1·8 (1·4 to 2·2) <·0001 2·0 (1·6 to 2·5)¶ <·0001 
3 8779/43676 20·1 (18·4 to 21·8) 5168/40156 12·9 (11·2 to 14·5) 1·7 (1·4 to 2·0) <·0001 1·8 (1·5 to 2·1)¶ <·0001 
Absolute difference‡ 
Relative change in testing: year 3 vs year  –1 
 11·9 (10·3 to 13·4) 
2·8 (2·4 to 3·2)§ 
 4·6 (3·3 to 6·0) 
1·6 (1·4 to 1·9) § 
 
1·7 (1·4 to 2·1)|| 
 
<·0001 
 
1·7 (1·4 to 2·1)||¶ 
 
<·0001 
Chlamydia positivity by time since randomisation †         
–1 250/2364** 10·6 (9·0 to 12·2) 310/2704** 11·5 (8·6 to 14·3) 0·9 (0·7 to 1·3) 0·5720 0·9 (0·6 to 1·2)¶ 0·4812 
0 535/5071** 10·6 (9·6 to 11·5) 485/5309**   9·1 (8·0 to 10·3) 1·2 (1·0 to 1·4) 0·0605 1·2 (1·0 to 1·4)¶ 0·0756 
1 573/5230** 11·0 (9·7 to 12·2) 457/4152** 11·0 (9·1 to 12·9) 1·0 (0·8 to 1·2) 0·9638 0·9 (0·8 to 1·2)¶ 0·5993 
2 634/7084**   8·9 (7·7 to 10·2) 438/4341** 10·1 (8·7 to 11·5) 0·9 (0·7 to 1·1) 0·2310 0·9 (0·7 to 1·1)¶ 0·2077 
3 498/7316**   6·8 (5·6 to   8·0) 394/4478**   8·8 (7·7 to   9·9) 0·8 (0·6 to 1·0) 0·0173 0·7 (0·6 to 0·9)¶ 0·0151 
Absolute difference‡ 
Relative change in positivity: year 3 vs year –1  
 –3·8 (-6·0 to –1·5) 
0·6 (0·5 to 0·8) § 
 –2·7 (–5·1 to –0·2) 
0·7 (0·5 to 1·0) § 
 
0·8 (0·6 to 1·2)|| 
 
0·3271 
 
0·8 (0·5 to 1·2)||¶ 
 
0·3304 
Chlamydia retesting (10-15 months) after a negative test 
result by time since randomisation† 
        
–1 167/2193   7·6 (6·3 to 8·9) 189/2489 7·6 (6·3 to 8·8) 1·0 (0·8 to 1·3) 0·9804 1·0 (0·8 to 1·3)¶ 0·8220 
0 397/4716   8·4 (7·1 to 9·7) 272/5000 5·4 (4·6 to 6·3) 1·6 (1·3 to 2·0) <·0001 1·7 (1·3 to 2·1)¶ <·0001 
1 506/4880 10·4 (8·7 to 12·1) 269/3862 7·0 (6·1 to 7·9) 1·5 (1·2 to 1·9) <·0001 1·6 (1·3 to 2·0)¶ <·0001 
2 610/6690   9·1 (8·3 to 9·9) 310/4075 7·6 (6·3 to 8·9) 1·2 (1·0 to 1·5) 0·0603 1·3 (1·1 to 1·6)¶ 0·0130 
3 260/7010   3·7 (2·2 to 5·2)   81/4236 1·9 (1·2 to 2·7) 2·0 (1·1 to 3·5) 0·0182 2·1 (1·2 to 3·8)¶ 0·0147 
Absolute difference‡ 
Relative change in retesting: year 3 vs year –1 
 –3·9 (–5·6 to –2·3) 
0·5 (0·3 to 0·7) § 
 –5·7 (–7·0 to –4·4) 
0·2 (0·2 to 0·4) § 
 
2·0 (1·1 to 3·5)|| 
 
0·0196 
 
2·0 (1·1 to 3·6)||¶ 
 
0·0149 
Chlamydia retesting (6 weeks - 6 months) after a positive 
test result by time since randomisation† 
        
–1  46/250 18·4 (13·6 to 23·2) 49/310 15·8 (10·7 to 20·9) 1·2 (0·7 to 1·9) 0·4543 1·2 (0·7 to 1·9)†† 0·4673 
0 118/535 22·1 (18·2 to 25·9) 93/485 19·2 (15·2 to 23·2) 1·2 (0·9 to 1·7) 0·2976 1·2 (0·9 to 1·7)¶ 0·2572 
1 159/573 27·7 (23·9 to 31·6) 90/457 19·7 (16·2 to 23·2) 1·6 (1·2 to 2·1) 0·0017 1·6 (1·2 to 2·2)¶ 0·0015 
2 158/634 24·9 (22·2 to 27·7) 84/438 19·2 (14·0 to 24·3) 1·4 (1·0 to 2·0) 0·0608 1·4 (1·0 to 2·0)†† 0·0611 
3 113/498 22·7 (18·9 to 26·5) 68/394 17·3 (13·1 to 21·4) 1·4 (1·0 to 2·0) 0·0537 1·6 (1·1 to 2·2)¶ 0·0103 
Absolute difference‡ 
Relative change in retesting:  year 3 vs year –1 
 4·3 (–1·5 to 10·0) 
1·3 (0·9 to 1·9) § 
 1·5 (–5·8 to 8·7) 
1·1 (0·7 to 1·9) § 
 
1·2 (0·6 to 2·2)|| 
 
0·6284 
 
1·2 (0·6 to 2·3)||¶ 
 
0·5277 
Repeat chlamydia infection (6 weeks – 6 months) after a 
positive test result by by time since randomisation† 
        
–1   5/46 10·9 (1·3 to 20·5) 10/49 20·4 (6·2 to 34·7) 0·5 (0·1 to 1·7) 0·2470 0·3 (0·1 to 1·0)¶ 0·0515 
0 15/118 12·7 (7·0 to 18·4) 12/93 12·9 (7·0 to 18·8) 1·0 (0·5 to 2·0) 0·9621 1·0 (0·5 to 2·0)‡‡ 0·9680 
1 22/159 13·8 (9·5 to 18·2) 10/90 11·1 (6·5 to 15·7) 1·3 (0·7 to 2·3) 0·3871 1·3 (0·7 to 2·3)†† 0·4378 
2 20/158 12·7 (6·3 to 19·0) 13/84 15·5 (7·1 to 23·8) 0·8 (0·3 to 1·8) 0·5770 0·8 (0·3 to 1·7)¶ 0·4837 
3 12/113 10·6 (4·4 to 16·9)   5/68   7·4 (0·0 to 14·8) 1·5 (0·4 to 5·1) 0·5187 1·4 (0·4 to 5·1)¶ 0·5650 
Absolute difference‡ 
Relative change in repeat infection:  year 3 vs year –1 
 –0·3 (–12·3 to 11·8) 
1·0 (0·3 to 3·4) § 
 –13·1(–23·3to –2·8) 
0·3 (0·1 to 0·7) § 
 
3·1 (0·7 to 13·8)|| 
 
0·1287 
 
3·6(0·9 to 14·2)||¶ 
 
0·0724 
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OR = Odds Ratio; CI = Confidence Interval 
* OR is for intervention versus control. † Time since randomisation refers to time since the start of the intervention period in each cluster and is defined as :  -1 is defined as 
the (24-13) months before randomisation; 0 is defined as (12-1) months before randomisation, prevalence survey 1 was conducted during this time; 1 as (1-12) months after 
randomisation; 2 as (13-24) months after randomisation; 3 as (25-36) months after randomisation. ‡ Absolute difference between relative year 3 and year –1. § Odds ratio for 
relative year 3 vs year –1. ||Odds ratio for intervention vs control for year 3 vs year –1. ** The denominator for chlamydia positivity is not equivalent to the number of 
chlamydia tests undertaken because chlamydia test results are not always stored electronically in the medical records at each clinic. Positivity is calculated based on the 
number of tests for which test results were stored electronically. ¶ Adjusted for gender, age group and socioeconomic status of clusters. †† Adjusted for age and gender. ‡‡ 
Adjusted for gender only. 
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Supplementary Table S2: Subgroup analyses of primary outcome – chlamydia prevalence 
Subgroup  Intervention Control Unadjusted 
Treatment effect 
Interaction 
test 
  n/N Prevalence (%)  
(95%CI) 
n/N Prevalence (%)  
(95%CI) 
OR* 
(95% CI) 
P value P value† 
Male Survey 1 
Survey 2 
33/557 
19/621 
5·9 (4·0 to 7·8) 
3·1 (1·8 to 4·4) 
27/531 
18/487 
5·1 (3·5 to 6·7) 
3·7 (2·0 to 5·4) 
0·7 
(0·3 to 1·6) 
 
0·3814 
 
0·4547 
 Female Survey 1 
Survey 2 
59/1276 
57/1616 
4·6 (3·3 to 5·9) 
3·5 (2·5 to 4·6) 
61/1394 
41/1229 
4·4 (3·1 to 5·6) 
3·3 (2·1 to 4·5) 
1·0 
(0·5 to 1·8) 
 
0·9732 
Age [16-19 years] Survey 1 
Survey 2 
35/432 
34/570 
8·1 (5·3 to 10·9) 
6·0 (3·9 to 8·1) 
35/521 
23/424 
6·7 (4·4 to 9·1) 
5·4 (3·0 to 7·9) 
0·9 
(0·4 to 2·1) 
 
0·8028 
 
 
 
0·7352 
Age [20-24 years] Survey 1 
Survey 2 
43/714 
26/834 
6·0 (4·0 to 8·0) 
3·1 (1·9 to 4·3) 
41/697 
28/696 
5·9 (3·9 to 7·9) 
4·0 (2·6 to 5·4) 
0·7 
(0·4 to 1·4) 
 
0·3341 
Age [25-29 years] Survey 1 
Survey 2 
14/687 
16/833 
2·0 (1·0 to 3·1) 
1·9 (1·0 to 2·9) 
12/707 
8/596 
1·7 (1·0 to 2·4) 
1·3 (0·2 to 2·5) 
1·2 
(0·4 to 4·0) 
 
0·7834 
Aboriginal/Torres Strait Islander Survey 1 
Survey 2 
8/103 
8/164 
7·8 (2·5 to 13·0) 
4·9 (1·4 to   8·3) 
6/124 
4/128 
4·8 (2·1 to 7·6) 
3·1 (0·9 to 5·3) 
0·9 
(0·2 to 4·0) 
 
0·9373 
 
 
0·9295 Not (Aboriginal/Torres Strait Islander) Survey 1 
Survey 2 
77/1578 
68/2015 
4·9 (3·6 to 6·1) 
3·4 (2·7 to 4·0) 
75/1662 
54/1562 
4·5 (3·3 to 5·7) 
3·5 (2·3 to 4·6) 
0·9 
(0·5 to 1·5) 
 
0·6546 
Cluster chlamydia prevalence prior to 
randomisation < 3%‡ 
Survey 1 
Survey 2 
11/590 
24/729 
1·9 (1·0 to 2·7) 
3·3 (2·1 to 4·5) 
7/487 
20/531 
1·4 (0·6 to 2·3) 
3·8 (1·8 to 5·8) 
0·7 
(0·3 to 1·8) 
 
0·4159 
 
 
0·5813 Cluster chlamydia prevalence prior to 
randomisation ≥ 3%‡ 
Survey 1 
Survey 2 
81/1243 
52/1508 
6·5 (5·3 to 7·7) 
3·4 (2·6 to 4·3) 
81/1438 
39/1185 
5·6 (4·6 to 6·6) 
3·3 (1·9 to 4·6) 
0·9 
(0·5 to 1·6) 
 
0·7559 
Cluster chlamydia testing in the 12 months 
prior to randomisation < 6%§ 
Survey 1 
Survey 2 
14/299 
14/322 
4·7 (1·9 to 7·4) 
4·3 (2·4 to 6·3) 
13/281 
11/262 
4·6 (2·4 to 6·8) 
4·2 (0·2 to 8·2) 
1·0  
(0·3 to 3·7) 
 
0·9604 
 
 
0·7964 Cluster chlamydia testing in the 12 months 
prior to randomisation ≥ 6%§ 
Survey 1 
Survey 2 
78/1534 
62/1915 
5·1 (3·7 to 6·5) 
3·2 (2·5 to 4·0) 
75/1644 
48/1454 
4·6 (3·3 to 5·8) 
3·3 (2·2 to 4·4) 
0·9 
(0·5 to 1·5) 
 
0·6052 
OR = Odds Ratio; CI = Confidence Interval 
* OR is for the interaction between randomisation group and survey 1 versus 2. † Interaction test between study group and variable of interest. ‡ Based on survey 1 
prevalence cut-point of 3% used in the randomisation algorithm. § Based on chlamydia testing cut-point of 6% used in the randomisation algorithm.  
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Supplementary Table S3: Secondary analysis of primary outcome chlamydia prevalence, in clinics that adhered to their randomisation allocation* 
 Intervention Control Unadjusted Adjusted 
Treatment effect Treatment effect 
Primary outcome n/N Prevalence (%)  
(95%CI) 
n/N Prevalence (%)  
(95%CI) 
OR† 
(95% CI) 
P value OR†‡ 
(95% CI) 
P value 
Chlamydia prevalence 
Survey 1 
Survey 2 
Difference: survey 2-survey 1 
 
78/1623 
67/2009 
 
4·8 (3·5 to 6·1) 
3·3 (2·6 to 4·1) 
–1·5 (–2·9 to –0·1) 
 
33/793 
27/669 
 
4·2 (2·5 to 5·8) 
4·0 (1·6 to 6·5) 
–0·1 (–3·1 to 3·0) 
 
0·7 
(0·3 to 1·6) 
 
0·3990 
 
0·7 
(0·3 to 1·7) 
 
0·4342 
Treatment effect: difference (intervention-control)  –1·4 (95% CI –4·7 to 1·9 p=0·4096)§     
OR = Odds Ratio; CI = Confidence Interval 
* Analysis is limited to intervention clinics testing ≥10·7% and control clinics testing <10·7% in the 12 months prior to survey 2, irrespective of the cluster’s testing 
performance before the start of the trial. A total of 23 intervention and 11 control clusters were included in the analysis. †OR is for the interaction between randomisation 
group and survey 1 versus 2.  ‡ Adjusted for gender, age group, socioeconomic status of clusters. § Unadjusted treatment effect calculated as the difference between survey2–
survey1 for intervention clusters and survey 2 – survey 1 for control clusters. 
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Supplementary Table S4: Subgroup analyses of secondary outcomes – chlamydia testing  
 
 
 Intervention Control Unadjusted Interaction 
test Treatment effect 
Subgroup Chlamydia testing by time since randomisation* n/N Proportion (%) 
(95%CI) 
n/N Proportion (%) 
(95%CI) 
OR 
(95% CI) 
P value P value† 
Males –1   636/14061   4·5 (3·9 to 5·2)   711/15731 4·5 (4·0 to 5·1)  1·0 (0·8 to 1·2) 0·9936 0·9058 
0 1560/17998   8·7 (7·8 to 9·5) 1532/18780 8·2 (7·2 to 9·1) 1·1 (0·9 to 1·3) 0·4201 0·2040 
1 1560/18490   8·4 (7·4 to 9·5) 1115/19061 5·8 (4·7 to 7·0) 1·5 (1·2 to 1·9) 0·0015 0·0792 
2 2304/18552 12·4 (10·1 to 14·8) 1216/18465 6·6 (5·5 to 7·7) 2·0 (1·5 to 2·6) <·0001 0·1225 
3 2296/18212 12·6 (11·2 to 14·0) 1230/16952 7·3 (6·1 to 8·5) 1·8 (1·5 to 2·3) <·0001 0·1748 
Females –1 2166/20082 10·8 (9·1 to 12·5) 2396/22044 10·9 (9·5 to 12·2) 1·0 (0·8 to 1·2) 0·9380  
0 4333/24420 17·7 (16·2 to 19·3) 4583/25482 18·0 (16·4 to 19·6) 1·0 (0·8 to 1·1) 0·8253  
1 4704/25478 18·5 (16·2 to 20·8) 3890/25605 15·2 (13·0 to 17·4) 1·3 (1·0 to 1·6) 0·0373  
2 6190/25453 24·3 (21·4 to 27·3) 3874/24973 15·5 (13·4 to 17·6) 1·8 (1·4 to 2·2) <·0001  
3 6483/25464 25·5 (23·5 to 27·5) 3938/23204 17·0 (14·9 to 19·1) 1·7 (1·4 to 2·0) <·0001  
Age  
[16-19 years] 
–1 1016/11834   8·6 (7·4 to 9·7) 1121/13267   8·4 (7·4 to 9·5) 1·0 (0·8 to 1·2) 0·8607 0·8203 
0 1925/14282 13·5 (12·0 to 14·9) 1994/15522 12·8 (11·5 to 14·2) 1·1 (0·9 to 1·2) 0·5143 0·4995 
1 2114/14463 14·6 (12·6 to 16·6) 1721/15287 11·3 (9·5 to 13·0) 1·3 (1·1 to 1·7) 0·0097 0·3212 
2 2798/14145 19·8 (17·2 to 22·3) 1741/14781 11·8 (10·0 to 13·6) 1·8 (1·5 to 2·3) <·0001 0·8235 
3 2738/13744 19·9 (18·1 to 21·7) 1713/13576 12·6 (10·5 to 14·7) 1·7 (1·4 to 2·1) <·0001 0·9613 
Age  
[20-24 years] 
–1 1136/11675   9·7 (8·2 to 11·3) 1224/12499   9·8 (8·5 to 11·1) 1·0 (0·8 to 1·2) 0·9498  
0 2349/14786 15·9 (14·6 to 17·2) 2362/14608 16·2 (14·5 to 17·9) 1·0 (0·8 to 1·1) 0·7884  
1 2572/15283 16·8 (14·9 to 18·7) 1957/15076 13·0 (10·9 to 15·0) 1·4 (1·1 to 1·7) 0·0063  
2 3412/15416 22·1 (19·3 to 25·0) 1999/14697 13·6 (11·6 to 15·7) 1·8 (1·4 to 2·3) <·0001  
3 3542/15311 23·1 (21·2 to 25·1) 2073/13754 15·1 (13·2 to 16·9) 1·7 (1·4 to 2·0) <·0001  
Age  
[25-29 years] 
–1   650/10634   6·1 (5·1 to 7·2)   762/12009   6·3 (5·3 to 7·4) 1·0 (0·8 to 1·2) 0·7493  
0 1619/13350 12·1 (11·0 to 13·2) 1759/14132 12·4 (11·1 to 13·8) 1·0 (0·8 to 1·1) 0·7072  
1 1578/14222 11·1 (9·6 to 12·6) 1327/14303   9·3 (7·9 to 10·7) 1·2 (1·0 to 1·5) 0·0700  
2 2284/14444 15·8 (13·1 to 18·5) 1350/13960   9·7 (8·3 to 11·0) 1·8 (1·4 to 2·2) <·0001  
3 2499/14621 17·1 (15·5 to 18·7) 1382/12826 10·8 (9·4 to 12·1) 1·7 (1·4 to 2·0) <·0001  
OR = Odds Ratio; CI = Confidence Interval 
* Time since randomisation refers to time since the start of the intervention period in each cluster and is defined as : 1 is defined as the (24-13) months before randomisation; 
0 is defined as (12-1) months before randomisation, prevalence survey 1 was conducted during this time; 1 as (1-12) months after randomisation; 2 as (13-24) months after 
randomisation; 3 as (25-36) months after randomisation. † Interaction test between study group and variable of interest (gender or age).   
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Supplementary Table S5: Subgroup analyses of secondary outcomes – chlamydia positivity  
 
 
 Intervention Control Unadjusted Interaction 
test 
 
Treatment effect 
Subgroup Chlamydia positivity by time since randomisation*† n/N Proportion (%) 
(95%CI) 
n/N Proportion (%) 
(95%CI) 
OR 
(95% CI) 
P value P value‡ 
Male –1   98/519 18·9 (15·6 to 22·1) 107/602 17·8 (14·1 to 21·5) 1·1 (0·8 to 1·5) 0·6482 0·2450 
0 174/1288 13·5 (11·4 to 15·6) 167/1322 12·6 (10·9 to 14·4) 1·1 (0·9 to 1·4) 0·5135 0·4224 
1 190/1228 15·5 (13·6 to 17·3) 148/882 16·8 (14·1 to 19·4) 0·9 (0·7 to 1·1) 0·4059 0·4472 
2 225/1821 12·4 (10·1 to 14·6) 151/994 15·2 (12·9 to 17·5) 0·8 (0·6 to 1·0) 0·0776 0·2773 
3 179/1827   9·8 (7·3 to 12·3) 133/1044 12·7 (10·4 to 15·1) 0·7 (0·5 to 1·0) 0·0865 0·9583 
Female –1 152/1845 8·2 (6·9 to 9·6) 203/2102 9·7 (6·5 to 12·8) 0·8 (0·6 to 1·2) 0·3796  
0 361/3783 9·5 (8·6 to 10·5) 318/3987 8·0 (6·6 to 9·3) 1·2 (1·0 to 1·5) 0·0659  
1 383/4002 9·6 (8·2 to 10·9) 309/3270 9·4 (7·5 to 11·4) 1·0 (0·8 to 1·3) 0·9185  
2 409/5263 7·8 (6·6 to 9·0) 287/3347 8·6 (7·2 to 9·9) 0·9 (0·7 to 1·1) 0·3643  
3 319/5489 5·8 (4·9 to 6·8) 261/3434 7·6 (6·4 to 8·8) 0·8 (0·6 to 0·9) 0·0160  
Age  
[16-19 years] 
–1 118/842 14·0 (12·0 to 16·0) 125/967 12·9 (9·6 to 16·2) 1·1 (0·8 to 1·5) 0·5746 0·1410 
0 256/1642 15·6 (13·3 to 17·9) 190/1704 11·2 (8·8 to 13·5) 1·5 (1·1 to 1·9) 0·0071 0·0082 
1 253/1764 14·3 (12·1 to 16·5) 197/1402 14·1 (11·2 to 16·9) 1·0 (0·8 to 1·4) 0·8699 0·1486 
2 277/2291 12·1 (10·0 to 14·2) 179/1477 12·1 (9·6 to 14·6) 1·0 (0·7 to 1·3) 0·9860 0·2613 
3 203/2251   9·0 (6·7 to 11·4) 161/1460 11·0 (9·4 to 12·7) 0·8 (0·6 to 1·1) 0·1717 0·2522 
Age  
[20-24 years] 
–1 107/974 11·0 (8·4 to 13·5) 147/1087 13·5 (10·5 to 16·6) 0·8 (0·6 to 1·1) 0·1927  
0 220/2023 10·9 (9·8 to 12·0) 208/2050 10·1 (8·8 to 11·5) 1·1 (0·9 to 1·3) 0·3978  
1 228/2142 10·6 (8·9 to 12·4) 201/1637 12·3 (9·8 to 14·7) 0·9 (0·6 to 1·1) 0·2609  
2 267/2867   9·3 (7·8 to 10·8) 187/1708 10·9 (9·3 to 12·6) 0·8 (0·7 to 1·1) 0·1380  
3 201/2939   6·8 (5·7 to   7·9) 173/1802   9·6 (8·4 to 10·8) 0·7 (0·6 to 0·9) 0·0007  
Age  
[25-29 years] 
–1 25/548 4·6 (2·8 to 6·3) 38/650 5·8 (2·7 to 9·0) 0·8 (0·4 to 1·5) 0·4437  
0 59/1406 4·2 (3·1 to 5·3) 87/1555 5·6 (4·6 to 6·6) 0·7 (0·5 to 1·0) 0·0582  
1 92/1324 6·9 (5·1 to 8·8) 59/1113 5·3 (4·1 to 6·5) 1·3 (0·9 to 1·9) 0·1105  
2 90/1926 4·7 (3·6 to 5·8) 72/1156 6·2 (4·9 to 7·6) 0·7 (0·5 to 1·0) 0·0701  
3 94/2126 4·4 (3·5 to 5·3) 60/1216 4·9 (3·6 to 6·3) 0·9 (0·6 to 1·3) 0·5213  
OR = Odds Ratio; CI = Confidence Interval 
* Time since randomisation refers to time since the start of the intervention period in each cluster and is defined as :  -1 is defined as the (24-13) months before 
randomisation; 0 is defined as (12-1) months before randomisation, prevalence survey 1 was conducted during this time; 1 as (1-12) months after randomisation; 2 as (13-24) 
months after randomisation; 3 as (25-36) months after randomisation. †The denominator for chlamydia positivity is not equivalent to the number of chlamydia tests 
undertaken because chlamydia test results are not always stored electronically in the medical records at each clinic. Positivity is calculated based on the number of tests for 
which test results were stored electronically.  ‡ Interaction test between study group and variable of interest (gender or age). 
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Supplementary Table S6: Subgroup analysis of secondary outcomes –  retesting within 10 to 15 months after a negative test  
 
 
 Intervention Control Unadjusted Interaction 
test 
 
Treatment effect 
Subgroup Chlamydia retesting by time since randomisation* n/N Proportion (%) 
(95%CI) 
n/N Proportion (%) 
(95%CI) 
OR 
(95% CI) 
P value P value† 
Male –1 22/443 5·0 (2·7 to 7·2) 22/513 4·3 (2·9 to 5·7) 1·2 (0·7 to 2·1) 0·5964 0·5895 
0 56/1158 4·8 (3·2 to 6·5) 29/1206 2·4 (1·2 to 3·6) 2·1(1·1 to 3·8) 0·0179 0·3697 
1 62/1087 5·7 (4·1 to 7·3) 31/770 4·0 (2·0 to 6·0) 1·4 (0·8 to 2·6) 0·2142 0·7525 
2 85/1653 5·1 (4·1 to 6·2) 40/879 4·6 (3·1 to 6·0) 1·1 (0·8 to 1·7) 0·5160 0·6263 
3 48/1693 2·8 (1·4 to 4·3)  9/950 0·9 (0·4 to 1·5) 3·1 (1·4 to 6·6) 0·0044 0·1735 
Female –1 145/1750   8·3 (6·7 to   9·9) 167/1976 8·5 (7·0 to 9·9) 1·0 (0·7 to 1·3) 0·8768  
0 341/3558   9·6 (7·9 to 11·2) 243/3794 6·4 (5·4 to 7·4) 1·5 (1·2 to 2·0) 0·0004  
1 444/3793 11·7 (9·7 to 13·7) 238/3092 7·7 (6·7 to 8·7) 1·6 (1·3 to 2·0) <·0001  
2 525/5037 10·4 (9·4 to 11·5) 270/3196 8·4 (6·9 to 10·0) 1·3 (1·0 to 1·6) 0·0374  
3 212/5317   4·0 (2·4 to 5·6) 72/3286 2·2 (1·3 to 3·1) 1·9 (1·0 to 3·3) 0·0372  
Age  
[16-19 years] 
–1   78/760 10·3 (8·1 to 12·5)   88/883 10·0 (7·8 to 12·1) 1·0 (0·7 to 1·4) 0·8449 0·5510 
0 164/1523 10·8 (8·6 to 12·9) 116/1644   7·1 (5·9 to   8·2) 1·6 (1·2 to 2·1) 0·0009 0·7790 
1 251/1822 13·8 (11·4 to 16·2) 123/1411   8·7 (7·2 to 10·2) 1·7 (1·3 to 2·2) 0·0001 0·3541 
2 302/2515 12·0 (10·3 to 13·7) 160/1610   9·9 (8·1 to 11·7)  1·2 (1·0 to 1·6) 0·0937 0·9964 
3 112/2723   4·1 (2·5 to 5·7)   46/1752   2·6 (1·5 to 3·8) 1·6 (0·9 to 2·8) 0·1173 0·1092 
Age  
[20-24 years] 
–1   67/899 7·5 (5·9 to 9·1)   68/983 6·9 (5·2 to 8·7) 1·1 (0·8 to 1·5) 0·6490  
0 166/1856 8·9 (7·7 to 10·2) 105/1892 5·5 (4·4 to 6·7) 1·7 (1·3 to 2·2) <·0001  
1 182/1890 9·6 (7·9 to 11·4) 110/1438 7·6 (5·8 to 9·5) 1·3 (0·9 to 1·8) 0·1232  
2 211/2529 8·3 (6·9 to 9·8) 103/1485 6·9 (5·3 to 8·6) 1·2 (0·9 to 1·7) 0·1970  
3 105/2583 4·1 (2·0 to 6·2)   28/1530 1·8 (0·9 to 2·7) 2·3 (1·1 to 4·7) 0·0248  
Age  
[25 to 29 
years] 
–1 22/534 4·1 (2·6 to 5·6) 33/623 5·3 (3·2 to 7·3) 0·8 (0·4 to 1·3) 0·3360  
0 67/1337 5·0 (3·7 to 6·3) 51/1464 3·5 (2·4 to 4·6) 1·5 (1·0 to 2·2) 0·0696  
1 73/1168 6·3 (4·8 to 7·7) 36/1013 3·6 (2·5 to 4·6) 1·8 (1·2 to 2·6) 0·0019  
2 97/1646 5·9 (4·8 to 7·0) 47/980 4·8 (3·3 to 6·3) 1·2 (0·9 to 1·8) 0·2538  
3 43/1704 2·5 (1·5 to 3·5)  7/954 0·7 (0·2 to 1·3) 3·5 (1·6 to 7·8) 0·0020  
OR = Odds Ratio; CI = Confidence Interval 
* Time since randomisation refers to time since the start of the intervention period in each cluster and is defined as :  -1 is defined as the (24-13) months before 
randomisation; 0 is defined as (12-1) months before randomisation, prevalence survey 1 was conducted during this time; 1 as (1-12) months after randomisation; 2 as (13-24) 
months after randomisation; 3 as (25-36) months after randomisation. † Interaction test between study group and variable of interest (gender or age).  
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Supplementary Table S7: Secondary outcomes –  alternative definitions of retesting after a positive test 
 Intervention Control Unadjusted Adjusted 
Treatment effect Treatment effect 
Retesting after a positive test 
 
n/N 
 
Proportion (%) 
(95%CI) 
n/N 
 
Proportion (%) 
(95%CI) 
OR* 
(95% CI) 
P 
value 
OR* 
(95% CI) 
P 
value 
Chlamydia retesting (< 3 weeks) after a positive test result by time since 
randomisation† 
        
–1  30/250 12·0 (6·3 to 17·7)  38/310 12·3 (6·9 to 17·6) 1·0 (0·5 to 2·0) 0·9469 1·0 (0·5 to 2·2)|| 0·9252 
0  50/535   9·3 (6·3 to 12·4)  70/485 14·1 (11·2 to 17·6) 0·6 (0·4 to 0·9) 0·0232 0·7 (0·4 to 1·0)¶ 0·0749 
1  57/573   9·9 (5·9 to 14·0)  71/457 15·5 (11·9 to 19·2) 0·6 (0·4 to 1·0) 0·0502 0·6 (0·4 to 1·0) || 0·0464 
2  61/634   9·6 (7·3 to 11·9)  66/438 15·1 (11·0 to 19·2) 0·6 (0·4 to 0·9) 0·0131 0·6 (0·4 to 0·9) ¶ 0·0101 
3  48/498   9·6 (6·6 to 12·7)  44/394 11·2 (7·5 to 14·9) 0·8 (0·5 to 1·4) 0·5135 0·9 (0·6 to 1·5) ¶ 0·7375 
Chlamydia retesting (6 weeks – 4 months) after a positive test result by time 
since randomisation† 
        
–1  36/250 14·4 (10·4 to 18·4) 34/310 11·0 (6·8 to 15·1) 1·4 (0·8 to 2·3) 0·2367 1·3 (0·8 to 2·3) || 0·2737 
0  93/535 17·4 (14·4 to 20·4) 73/485 15·1 (11·1 to 19·0) 1·2 (0·8 to 1·7) 0·3510 1·2 (0·8 to 1·7) ¶ 0·2914 
1 108/573 18·8 (15·7 to 22·0) 62/457 13·6 (9·4 to 17·7) 1·5 (1·0 to 2·2) 0·0516 1·5 (1·0 to 2·3) ¶ 0·0544 
2 117/634 18·5 (15·7 to 21·2) 61/438 13·9 (10·3 to 17·5) 1·4 (1·0 to 2·0) 0·0523 1·4 (1·0 to 2·0) || 0·0531 
3  92/498 18·5 (14·6 to 22·3) 49/394 12·4 (9·1 to 15·8) 1·6 (1·1 to 2·3) 0·0177 1·7 (1·1 to 2·6) ¶ 0·0086 
OR = Odds Ratio; CI = Confidence Interval 
* OR is for intervention versus control. † Time since randomisation refers to time since the start of the intervention period in each cluster and is defined as :   to 1 is defined 
as the (24-13) months before randomisation; 0 is defined as (12-1) months before randomisation, prevalence survey 1 was conducted during this time; 1 as (1-12) months 
after randomisation; 2 as (13-24) months after randomisation; 3 as (25-36) months after randomisation|| Adjusted for age and gender. ¶ Adjusted for gender, age group and 
socioeconomic status of clusters.  
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